Skip to content

Advertisement

  • Poster presentation
  • Open Access

When is a autologous bone marrow transplantation indicated in the treatment of juvenile systemic sclerorsis? Results of a multinational survey of Pediatric Rheumatologist

  • 1,
  • 1 and
  • 2
Pediatric Rheumatology20119 (Suppl 1) :P73

https://doi.org/10.1186/1546-0096-9-S1-P73

  • Published:

Keywords

  • Ejection Fraction
  • Cyclophosphamide
  • Ventricular Ejection
  • Retrospective Cohort
  • Scleroderma

The five year survival of juvenile systemic sclerosis (jSSc) is around 95%. Patients, who died in the two retrospective cohorts, died mostly in the first 24 months of disease course. Autologous bone marrow transplantation (ABMT) seems to be a promising therapeutic approach for adult patients ( ASTIS (EU) and SCOT (USA)Trial) with severe disease course. Around 8 patients with jSSc are transplanted according the EBMT registry. Currently no consent based inclusion or exclusion criteria for ABMT in jSSc exists.

Aim of the survey was to get a feeling from paediatric rheumatologists, when they would apply autologous bone marrow transplantation as a treatment option.

Paediatric Rheumatologist - members of the PRES Juvenile Scleroderma Working Group and participants of the Paediatric Rheumatology E-mail Board were asked via Internet to fill out the survey

22 centres responded, all of them were academic centres. BMT would be considered for 14 of the 22 colleagues after nonresponse to cyclophosphamide, 10 of 22 after non response to two DMARDs and 12 of 22 after nonresponse to Rituximab. 19 of 22 would consider transplantation if the CHAQ score ≤ 2 , 20 of 22 if the CHQ is less than 40%. 21 of 22 would think about transplantation if the modified Rodnan skin score is more than 30 and 15 of 22 if the DLCO is less than 50%, 18 of 22 if the WHO functional class is 3, 14 of 22 if the FVC less than 60%, 15 of 22 if the pulmonary arterial pressure more than 40 mm/hg and 11 of 22 if left ventricular ejection fraction is less than 40%.

This survey represents an impression, when pediatric rheumatologist would consider ABMT. It is a starting point for a possible evolving ABMT program for this orphan disease

Authors’ Affiliations

(1)
Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany
(2)
Rheumatology, Hopital Saint Louis, Paris, France

Copyright

© Foeldvari et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement